Compare +50 FDA De Novo providers: how to shortlist the right partner without wasting a review cycle

Teams moving into the De Novo pathway usually face the same planning problem: the device has no suitable predicate, risk controls are still evolving, and timelines can slide if strategy and evidence are not synchronized early. This directory gives you a practical way to compare provider models, pricing structures, and execution depth before you commit budget.

Why this provider category matters

The De Novo process is not only a submission writing task. It is a regulatory design task where classification rationale, risk controls, validation endpoints, and labeling claims must reinforce each other. A provider that only drafts text without influencing evidence plans can leave you with polished documents and unresolved substantive questions. A provider that only runs tests without a coherent regulatory narrative can create expensive data that does not answer FDA's likely review concerns.

Strong De Novo support combines five capabilities: early pathway strategy, risk management alignment, test and clinical planning, quality system integration, and high-fidelity submission execution. In practice, buyers usually trade off among these capabilities because firms specialize differently. Some are strategy-heavy boutique consultancies. Some are full-service contract research or testing networks. Some are documentation shops that depend on your internal team for decisions. Your shortlist should reflect the complexity of your device and the maturity of your internal regulatory function.

Provider types you will see

Keyword intent clusters this page targets

To align with high-intent buyer searches, this page and linked tools focus on recurring search patterns such as "de novo consultant cost," "FDA de novo timeline," "de novo submission support," "de novo clinical evidence requirements," and "how to choose de novo regulatory firm." These terms reflect evaluative intent, not top-of-funnel awareness intent, so content is decision-oriented and calculator-driven.

How to score providers in your first pass

Use a weighted scorecard rather than subjective call notes. Most teams can score 10-15 candidates in one week with a structured process. Start with these criteria:

• Pathway judgment quality: Do they explain why De Novo is appropriate versus 510(k), PMA, or a staged indication strategy?
• Evidence-design fluency: Can they translate claims into measurable endpoints and feasible studies?
• Cross-functional depth: Can they coordinate software, cybersecurity, biocompatibility, sterilization, and human factors where relevant?
• Authoring quality: Do sample deliverables show defensible logic, clean structure, and consistent terminology?
• Operating model fit: Are they willing to work with your existing labs, CROs, and internal owners?
• Commercial transparency: Is pricing fixed, milestone-based, or time-and-materials with clear assumptions?

Questions that separate strong providers from expensive project managers

Ask questions that force analytical specificity. For example: "What three reasons are most likely to trigger additional information requests for our device class hypothesis?" or "Which labeling claims should we defer until post-market data to reduce first-cycle risk?" High-quality providers answer with clear mechanisms and tradeoffs. Weak providers answer with general process language and no decision framework.

Also test accountability. Ask who owns final strategy decisions, who writes core sections, and who signs off on technical consistency across modules. If responsibility is diffused across many subcontractors, execution risk rises even when the pitch sounds comprehensive.

Commercial guardrails before contracting

Define objective deliverables and acceptance criteria per milestone. Tie payment to decision outputs, not just meeting count or "support." Require a version-controlled evidence map so every major claim maps to test data, literature, or rationale. Include change-order rules for scope expansion and cap pass-through costs unless pre-approved.

If you are buying partial support, document exactly what stays with your internal team. Ambiguity here is a common root cause of timeline slippage and budget overruns.

Suggested process for selecting from +50 providers

1. Run all three calculators to establish your working assumptions.
2. Create a longlist of 12-18 candidates using capability fit, not brand familiarity.
3. Issue a short scenario brief and collect written responses before live calls.
4. Score responses with a weighted matrix; only then schedule interviews.
5. Take 4-6 finalists through structured calls with identical questions.
6. Request one anonymized sample deliverable and one client reference per finalist.
7. Negotiate milestone definitions and governance cadence before signature.

Citations

Regulatory references used for this directory and linked calculators:

• FDA: De Novo Classification Request
• 21 CFR Part 860 - De Novo Classification
• FDA: Medical Device User Fee Amendments (MDUFA)
• FDA: Benefit-Risk Framework Guidance